MHRP and collaborators recently launched a Phase 1 trial that will evaluate safety, tolerability, and immunogenicity of varying doses of the Army’s novel ALFQ adjuvant in a candidate HIV vaccine to optimize adjuvant dosage.
The Walter Reed Army Institute of Research (WRAIR) has conducted a first-in-human evaluation of a novel malaria vaccine candidate containing the FMP013 antigen and the ALFQ adjuvant, both developed at WRAIR. Results were published August 30 in the journal Vaccine.
Mbeya, Tanzania – The Walter Reed Program-Tanzania (WRP-T) recently participated in the agricultural trade fair celebrating the “Nane Nane” public holiday recognizing the contributions of farmers. WRP-T's ’s exhibition at the fair highlighted WRP-T's HIV program interventions, the DREAMS initiative for adolescent girls and young women, and even offered COVID-19 vaccinations on site.
Tanzania’s agriculture minister, Hussein Bashe, expressed support for a group of adolescent girls and young women (AGYW) from the Kyela region to help them set up a cocoa farm as part of their entrepreneurship project under the Walter Reed Program-Tanzania (WRP-T) DREAMS program.
